Sign Up Today and Learn More About Ray Therapeutics Stock
Invest in or calculate the value of your shares in Ray Therapeutics or other pre-IPO companies through EquityZen's platform.
Ray Therapeutics Stock (RATH)
Ray Therapeutics is a biotech company developing optogenetic gene therapies for patients with blinding diseases.
About Ray Therapeutics Stock
Founded
2021
Headquarters
San Diego, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Ray Therapeutics Press Mentions
Stay in the know about the latest news on Ray Therapeutics
Ray Therapeutics Appoints Michael Murtagh as Chief Regulatory Officer
pharmiweb • Feb 17, 2026
Ray Therapeutics Appoints Michael Murtagh as Chief Regulatory Officer
businesswire • Feb 17, 2026
Gene therapy compositions and methods for treating diseases of the retina
patents • Feb 01, 2026
Ray Therapeutics Appoints Scott Braunstein, M.D., as Chairman of the Board of Directors
pharmiweb • Jan 09, 2026
Choroideremia Market Epidemiology Report 2025-2035: Pipeline Therapies, Drugs Sales, and Regional Outlook
einpresswire • Jul 14, 2025
Ray Therapeutics Management
Leadership team at Ray Therapeutics
Head of Regulatory Affairs
Kathrin Schalper
Board of Directors
Tiba Aynechi
Join now and verify your accreditation status to gain access to:
- Ray Therapeutics Current Valuation
- Ray Therapeutics Stock Price
- Ray Therapeutics Management
- Available deals in Ray Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Ray Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Ray Therapeutics Revenue and Financials
- Ray Therapeutics Highlights
- Ray Therapeutics Business Model
- Ray Therapeutics Risk Factors
- Ray Therapeutics Research Report from SACRA Research
Trading Ray Therapeutics Stock
How to invest in Ray Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Ray Therapeutics through EquityZen funds. These investments are made available by existing Ray Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Ray Therapeutics stock?
Shareholders can sell their Ray Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 430K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 52K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
